Last reviewed · How we verify
Mycophenolate mofetil withdrawal
At a glance
| Generic name | Mycophenolate mofetil withdrawal |
|---|---|
| Sponsor | University of Oslo School of Pharmacy |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial. (PHASE4)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Tocilizumab in Cardiac Transplantation (PHASE2)
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (PHASE2)
- 3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation (PHASE3)
- Belatacept in Heart Transplantation (PHASE2)
- Expanding Liver Transplant Immunosuppression Minimization Via Everolimus (PHASE2)
- A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |